-87%

est. 2Y upside i

HealthcarePre-Seed

Salt is the definitive contextual AI platform that unpacks the 'black box' of enterprise AI applications for life science and healthcare organizations. Execute complex, multi-model, nested swarms of general and specialized models in a visual-first IDE.

Rank

#1083

Sector

Life Sciences AI

Est. Liquidity

~5Y

Data Quality

Data: High

Salt AI operates in a high-growth, high-impact sector (Life Sciences AI orchestration) with a compelling product that addresses significant regulatory hurdles.

Last updated: March 10, 2026

Bull (25%)+350%

Salt AI becomes the leading compliant AI orchestration platform for life sciences, expanding its customer base significantly and achieving $50M+ ARR. An acquisition by a major pharma tech player or a successful Series B/C round values the company at $120-150M, providing substantial returns (350% upside).

Base (25%)+150%

Salt AI successfully captures a segment of the life sciences AI orchestration market, growing revenue to $20-30M ARR. An acquisition at $70-80M valuation provides a moderate return for common shareholders (150% upside) after accounting for liquidation preferences.

Bear (50%)-85%

Incumbents like Palantir or Microsoft launch directly competing compliant AI orchestration platforms, commoditizing Salt AI's offering. Growth stalls, and a down round or acquisition at $15-20M valuation results in common stock being worth little to nothing (-85% downside) after $13M in liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

45%

Investors hold $13M in liquidation preferences, meaning common stock holders would receive little to nothing in an exit at or below $13M, and significantly diluted returns in an exit up to $29M.

Dilution Risk

high

As a Pre-Series A company, Salt AI will require several more funding rounds (e.g., Series A, B, C) before a potential exit, each of which will likely lead to significant dilution for current equity holders. The company plans to begin fundraising a formal Series A round in early 2026.

Secondary Liquidity

none

Salt AI stock is not currently traded in the private markets, with no buyers or sellers at this time.

Questions to Ask at the Interview

Strategic questions based on Salt's data — designed to show you've done your homework.

  • 1

    “Given the competitive landscape with incumbents like Palantir and Databricks, how does Salt AI plan to maintain its differentiation and capture market share beyond its current niche in compliant life sciences workflows?”

  • 2

    “With plans to raise a formal Series A in early 2026, what are the key milestones and growth metrics the company aims to achieve to justify a significantly higher valuation and mitigate future dilution for existing equity holders?”

  • 3

    “Considering the current severe liquidation preference stack, what is the company's strategy to ensure meaningful returns for common stock holders in potential exit scenarios, and what is the anticipated timeline for a liquidity event?”

Community

Valuation Sentiment

Our model estimates -87% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.